2022 World Conference on Lung Cancer (ePosters)-EP08.01-091. Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront

EP08.01-091. Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront

Back to course

Pdf Summary

A multicenter retrospective study was conducted to assess the impact of neutrophil-to-lymphocyte ratio (dNLR) on outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) alone or in combination with chemotherapy. The study included a total of 285 patients enrolled between August 2012 and September 2021.<br /><br />The results showed that dNLR-score, based on dNLR at baseline and cycle 2, was associated with treatment outcomes in patients with advanced NSCLC undergoing immunotherapy alone or in combination with chemotherapy. Patients with persistently high dNLR had poorer outcomes. The dynamics of dNLR under treatment differed between immunotherapy monotherapy and combination with chemotherapy, with a higher rate of dNLR poor observed in the immunotherapy cohort.<br /><br />In terms of overall survival (OS), the dNLR-score significantly stratified the population into three prognostic groups: good, intermediate, and poor. The median OS in the good group was significantly longer compared to the intermediate and poor groups. Similarly, progression-free survival (PFS) was significantly associated with the dNLR-score in both the immunotherapy and immunotherapy-chemotherapy cohorts.<br /><br />Additional analysis showed that a higher proportion of patients with poor performance status (PS2) were observed in the immunotherapy-chemotherapy cohort compared to the immunotherapy cohort. The majority of patients in the immunotherapy cohort had PD-L1 expression of 50% or higher.<br /><br />In conclusion, the study suggests that dNLR-score based on dNLR at baseline and cycle 2 can be a useful biomarker for predicting treatment outcomes in patients with advanced NSCLC receiving immune checkpoint inhibitors alone or in combination with chemotherapy. Further research is needed to validate these findings and better understand the dynamic impact of dNLR during treatment.

Asset Subtitle

Teresa Gorria

Meta Tag

Speaker Teresa Gorria

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

neutrophil-to-lymphocyte ratio

dNLR

non-small cell lung cancer

NSCLC

immune checkpoint inhibitors

chemotherapy

treatment outcomes

overall survival

progression-free survival

performance status